Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Compare

423 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FHTX Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Foghorn

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FHTX Stock 12 Month Forecast

Average Price Target

$11.38

▲(127.60% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Foghorn Therapeutics in the last 3 months. The average price target is $11.38 with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a 127.60% change from the last price of $5.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,5.138461538461539,5.876923076923077,6.615384615384615,7.353846153846154,8.092307692307692,8.830769230769231,9.569230769230769,10.307692307692307,11.046153846153846,11.784615384615385,12.523076923076923,13.26153846153846,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.936923076923077,5.4738461538461545,6.010769230769231,6.547692307692309,7.084615384615385,7.621538461538462,8.15846153846154,8.695384615384615,9.232307692307693,9.76923076923077,10.306153846153848,10.843076923076923,{"y":11.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.753846153846154,5.107692307692308,5.461538461538462,5.815384615384616,6.1692307692307695,6.523076923076923,6.876923076923077,7.230769230769231,7.584615384615384,7.938461538461539,8.292307692307691,8.646153846153846,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$11.38

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jeet Mukherjee

BTIG

$11

Buy

120.00%

Upside

Initiated

12/18/25

Foghorn Therapeutics initiated with a Buy at BTIGFoghorn Therapeutics initiated with a Buy at BTIG

Yuan Zhi

B. Riley Securities

$10

Buy

100.00%

Upside

Reiterated

12/17/25

Analysts' Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$14

Buy

180.00%

Upside

Reiterated

12/17/25

Evercore ISI Sticks to Their Buy Rating for Foghorn Therapeutics (FHTX)

Laura Prendergast

Stifel Nicolaus

$12

Buy

140.00%

Upside

Initiated

12/04/25

Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast

Andres Y. Maldonado

H.C. Wainwright

$13

Buy

160.00%

Upside

Reiterated

11/17/25

Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics

Michael Schmidt

Guggenheim

$12

Buy

140.00%

Upside

Initiated

11/07/25

Foghorn Therapeutics initiated with a Buy at GuggenheimFoghorn Therapeutics initiated with a Buy at Guggenheim

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/05/25

Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

Silvan Tuerkcan

Citizens JMP

Buy

80.00%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Robert Driscoll

Wedbush

$10

Buy

100.00%

Upside

Reiterated

10/30/25

Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating

Vikram Purohit

Morgan Stanley

Hold

-20.00%

Downside

Reiterated

06/12/25

Morgan Stanley Reaffirms Their Hold Rating on Foghorn Therapeutics (FHTX)

Kalpit Patel

Wolfe Research

$10

Buy

100.00%

Upside

Initiated

01/29/25

Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jeet Mukherjee

BTIG

$11

Buy

120.00%

Upside

Initiated

12/18/25

Foghorn Therapeutics initiated with a Buy at BTIGFoghorn Therapeutics initiated with a Buy at BTIG

Yuan Zhi

B. Riley Securities

$10

Buy

100.00%

Upside

Reiterated

12/17/25

Analysts' Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$14

Buy

180.00%

Upside

Reiterated

12/17/25

Evercore ISI Sticks to Their Buy Rating for Foghorn Therapeutics (FHTX)

Laura Prendergast

Stifel Nicolaus

$12

Buy

140.00%

Upside

Initiated

12/04/25

Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast

Andres Y. Maldonado

H.C. Wainwright

$13

Buy

160.00%

Upside

Reiterated

11/17/25

Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics

Michael Schmidt

Guggenheim

$12

Buy

140.00%

Upside

Initiated

11/07/25

Foghorn Therapeutics initiated with a Buy at GuggenheimFoghorn Therapeutics initiated with a Buy at Guggenheim

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/05/25

Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

Silvan Tuerkcan

Citizens JMP

Buy

80.00%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Robert Driscoll

Wedbush

$10

Buy

100.00%

Upside

Reiterated

10/30/25

Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating

Vikram Purohit

Morgan Stanley

Hold

-20.00%

Downside

Reiterated

06/12/25

Morgan Stanley Reaffirms Their Hold Rating on Foghorn Therapeutics (FHTX)

Kalpit Patel

Wolfe Research

$10

Buy

100.00%

Upside

Initiated

01/29/25

Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Foghorn Therapeutics

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+6.36%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +6.36% per trade.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+9.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.62% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

4/5 ratings generated profit

Average Return

+6.78%

reiterated a buy rating last month

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +6.78% per trade.

2 Years

xxx

Success Rate

4/5 ratings generated profit

Average Return

+6.78%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +6.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FHTX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FHTX has received 12 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. FHTX average Analyst price target in the past 3 months is 11.38.

Each month's total comprises the sum of three months' worth of ratings.

FHTX Financial Forecast

FHTX Earnings Forecast

Next quarter’s earnings estimate for FHTX is -$0.25 with a range of -$0.37 to -$0.06. The previous quarter’s EPS was -$0.25. FHTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year FHTX has Performed in-line its overall industry.

FHTX Sales Forecast

Next quarter’s sales forecast for FHTX is $9.49M with a range of $2.86M to $25.00M. The previous quarter’s sales results were $8.15M. FHTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year FHTX has Performed in-line its overall industry.

FHTX Stock Forecast FAQ

What is FHTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Foghorn Therapeutics’s 12-month average price target is 11.38.

What is FHTX’s upside potential, based on the analysts’ average price target?

Foghorn Therapeutics has 127.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FHTX a Buy, Sell or Hold?

Foghorn Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Foghorn Therapeutics’s price target?

The average price target for Foghorn Therapeutics is 11.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $9.00. The average price target represents 127.60% Increase from the current price of $5.

What do analysts say about Foghorn Therapeutics?

Foghorn Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of FHTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

FHTX Analyst Ratings

FHTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Foghorn Therapeutics

FHTX Analyst Recommendation Trends

FHTX Financial Forecast

FHTX Earnings Forecast

FHTX Sales Forecast

FHTX Stock Forecast FAQ

Detailed List of Analyst Forecasts